Avedro and Japan’s Shinagawa LASIK Centers Announce Their Expanded Commercial Relationship

The Shinagawa LASIK Center in Tokyo has performed more Lasik surgeries than any other center in the world

WALTHAM, Mass.--(BUSINESS WIRE)-- Avedro, Inc announced today that Shinagawa LASIK Centers has made a significant investment in expanding its use of Avedro products. For the past 6 months, the Shinagawa LASIK Center in Tokyo has been using Avedro’s Lasik Xtra™ procedure to improve the corneal biomechanics in Lasik patients. Based on the clinical results achieved with Avedro’s technology in the Tokyo LASIK clinic, Shinagawa has now purchased additional Avedro KXL™ Systems for performing Lasik Xtra in its LASIK centers located in Tokyo, Nagaya, Osako, Sapporo and Fukuoka.

“We are extremely pleased with the KXL System and with the Lasik Xtra procedure. Lasik Xtra now makes it possible for Shinagawa LASIK Center to provide enhanced treatments to our current Lasik patients,” said Minoru Tomita, M.D., PhD, Executive Director, Shinagawa LASIK Center.

“The Shinagawa LASIK Center in Tokyo is on the forefront of the clinical application of corneal cross-linking with Lasik surgery,” said David Muller, PhD, CEO of Avedro. “Avedro is fortunate to have Dr. Tomita, a globally recognized ophthalmic thought leader and leading Lasik surgeon, working with us in advancing Lasik surgery with our KXL System and Lasik Xtra procedure. We are also privileged to be working with the Shinagawa LASIK Centers, universally recognized for their medical competency and technical innovation.”

Lasik Xtra is an accelerated cross-linking procedure that takes only minutes and is seamlessly integrated into a standard Lasik procedure to help restore corneal biomechanical strength after Lasik and return corneas to their pre-Lasik strength. Avedro’s KXL Systems have been sold into Canada, Latin America, Europe, the Middle East, Asia and Australia.

About Avedro, Inc.

Avedro is a privately held medical device and pharmaceutical company based in Waltham, MA. It developed the KXL System for performing Lasik Xtra and Accelerated Cross-linking. Avedro is currently in multi-centered US-based Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and post-Lasik ectasia. Additionally, Avedro is developing the science of Thermo-biomechanics for therapeutic applications. Keraflex® is the first technology Avedro has developed from its Thermo-biomechanics platform. The Keraflex procedure is a non-invasive, incision-less ophthalmic procedure for flattening the cornea without the removal of tissue, offering the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex and KXL are CE Marked and commercially available outside of the United States.

About Shinagawa LASIK Centers

The Shinagawa LASIK Centers are one of the world’s largest providers of refractive surgery. Operating throughout Japan and in Singapore, Shinagawa offers exceptional world-class patient care and offers all their patients a 3-year enhancement warranty should they need follow-up treatments.



CONTACT:

Avedro, Inc.
Kristen Gleason, 781-768-3400
[email protected]

KEYWORDS:   United States  Asia Pacific  North America  Massachusetts  Japan

INDUSTRY KEYWORDS:   Surgery  Health  Biotechnology  Medical Devices  Optical  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.